New webinar: optimizing miRNA-seq from biofluid samples


In recent years, the discovery that microRNAs are stable in biofluids has led to intense research into their utility in understanding diseases, as well as normal biology. miRNA-seq is emerging as a key technology for microRNA expression studies, but specific challenges have limited its use for biofluid microRNAs. That is, until now. On March 20, our miRNAseq expert Jonathan Shaffer will present a free 1-hour webinar about a new technology that optimizes miRNA-seq for biofluid microRNA research. Check out the abstract below, and sign up for the time that works best for you!

miRNAseq for liquid biopsy: robust detection from the lowest sample
Jonathan Shaffer, Ph.D. – QIAGEN
March 20 at 1 p.m. EST, 10 a.m. PST, 7 p.m. CET

(Editor’s note: This webinar has ended, but check out the recording here!)

microRNAs impact virtually all areas of biology including development, differentiation, signal transduction, infection, aging and disease. In circulation, these small noncoding regulatory RNAs are also promising biomarker candidates for both normal and disease biology. Found in virtually all biofluids including serum, plasma and cerebrospinal fluid, miRNAs are protected from degradation by exosomes, Ago2, HDL or other protective proteins. A challenge arises though that miRNAs are expressed at low levels in biofluids. As a result, expression analysis, particularly using next-generation sequencing (NGS), has proven to be difficult. Traditional small RNA library kits lack the sensitivity or specificity to adequately assess microRNA expression. Libraries prepared using these kits have been fraught with background products, such as adapter dimers and other RNAs, including hY4 Y RNA. These problems collectively manifest as a low mapping percentage to microRNA, a limited dynamic range and lost discovery potential. Recently, QIAGEN has released the QIAseq miRNA Library Kit that has been specifically designed to overcome the challenges associated with NGS library prep of microRNAs from biofluids. The innovative, gel-free workflow enables the preparation of robust libraries from even the most difficult, low RNA content biofluids. QIAseq miRNA maximizes your on-target microRNA reads, dynamic range and most importantly, your discovery potential.

Want to know more about QIAseq for miRNA in advance of the webinar? Check out the details here!


Ali Bierly

Ali Bierly, PhD is a Global Market Manager in Translational Sciences at QIAGEN, and has written on a number of scientific topics in the biotech industry as the author of QIAGEN's Reviews Online. She received her PhD from Cornell University in 2009, studying the immune response to a protozoan parasite, Toxoplasma gondii. Ali has a keen interest in the emerging importance of microRNA and other circulating nucleic acids as biomarkers for disease.

Your email address will not be published. Required fields are marked *